1. Hemolytic anemia is a type of
anemia caused by premature destruction of red blood cells (RBCs), resulting in
a shortened RBC lifespan.
2. Hemolysis may occur either
intravascularly (within blood vessels) or extravascularly (mainly in the spleen
and liver).
3. Hemolytic anemia may be
classified as hereditary (e.g., thalassemia, sickle cell anemia, hereditary
spherocytosis) or acquired (e.g., autoimmune hemolytic anemia, malaria, and
drug-induced hemolysis).
4. Increased RBC destruction
stimulates the bone marrow, resulting in reticulocytosis as a compensatory
response.
5. Laboratory findings typically include
decreased serum haptoglobin, increased unconjugated bilirubin, increased LDH,
and increased reticulocyte count.
6. Peripheral blood film may show
spherocytes, schistocytes, or other abnormal RBC shapes, depending on the
underlying cause.
7. Clinical features include pallor,
fatigue, jaundice, dark urine (particularly in intravascular hemolysis), and
splenomegaly.
8. Treatment depends on the
underlying cause and may include folic acid supplementation, corticosteroids
for autoimmune hemolysis, blood transfusion when indicated, or splenectomy in
selected cases.
Important point: The classical laboratory triad of hemolytic
anemia is increased unconjugated bilirubin, increased LDH, and decreased serum
haptoglobin.

0 Comments